Ensayos clínicos de Lupus en Illinois
14 estudios sobre Lupus buscan participantes en Illinois.
Ciudades en Illinois
Texto oficial del estudio (inglés)
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 13 nov 2026 · NCT07430306Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Willow Rheumatology Wellness, Willowbrook
ReclutandoFase 3
Edades de 12 a 100 · Todos los sexos · Actualizado el 9 nov 2026 · NCT06133972A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07438496A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
ReclutandoEstudio observacional
Edades de 16 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07175285A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
ReclutandoFase 1
Edades de 18 a 74 · Todos los sexos · Actualizado el 2 nov 2026 · NCT07085104A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
ReclutandoFase 3
Edades de 16 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06617325A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
ReclutandoFase 1
Edades de 18 a 70 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06925542A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 20 oct 2026 · NCT07607964RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center - Accepting Adult and Adolescent Patients, Chicago
ReclutandoFase 1/2
Edades de 12 a 65 · Todos los sexos · Actualizado el 6 oct 2026 · NCT06121297An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
ReclutandoFase 3
Edades de 5 a 17 · Todos los sexos · Actualizado el 30 sept 2026 · NCT05835310A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
ReclutandoFase 2
Edades de 16 a 70 · Todos los sexos · Actualizado el 17 sept 2026 · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
ReclutandoFase 1/2
Edades de 18 a 70 · Todos los sexos · Actualizado el 10 sept 2026 · NCT06897930A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 10 ago 2026 · NCT06977724Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
ReclutandoEstudio observacional
Edades de 18 a 110 · Todos los sexos · Actualizado el 15 abr 2026 · NCT05934149De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.